Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors
Pulmonary arterial hypertension (PAH) is known to develop as a consequence of multiple genetic and/or non-genetic factors. A 27-year-old woman with chronic hepatitis C virus (HCV) infection developed severe PAH after interferon (IFN) therapy. Although most of the reported clinical courses of IFN-ind...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2017/05/01, Vol.56(9), pp.1061-1065 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1065 |
|---|---|
| container_issue | 9 |
| container_start_page | 1061 |
| container_title | Internal Medicine |
| container_volume | 56 |
| creator | Tsuchiya, Hiromi Kioka, Hidetaka Ozu, Kentaro Ohtani, Tomohito Yamaguchi, Osamu Yazaki, Yoshikazu Yamauchi-Takihara, Keiko Sakata, Yasushi |
| description | Pulmonary arterial hypertension (PAH) is known to develop as a consequence of multiple genetic and/or non-genetic factors. A 27-year-old woman with chronic hepatitis C virus (HCV) infection developed severe PAH after interferon (IFN) therapy. Although most of the reported clinical courses of IFN-induced PAH are poor despite the discontinuation of IFN, the present patient was successfully treated with a triple combination therapy. In this report, we discuss the crosstalk among chronic HCV infection, IFN therapy, autoimmune disorders, and portal hypertension in the pathogenesis and development of PAH. |
| doi_str_mv | 10.2169/internalmedicine.56.7822 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5478568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014534247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-df3b62a4430d0930253ed4a377bc638b4782ffa732e259952f353713ba12cf383</originalsourceid><addsrcrecordid>eNptkcGO0zAQhiMEYrsLr4AsceGSkthxEnNAQtUurbTACi1crYkzaV1cJ2s7QB9k3xeHlgpWXMay_M3_e-ZPEpJnc5qX4rW2AZ0Fs8NWK21xzst5VVP6KJnlrBBpRRl_nMwykdcpjeUsOfd-m2WsrgR9mpzRuuA1y9ksuV9NUh263pLbDToY9uTyJyh0DQRsyc1odr0FtyfL_YAuoPU6otoSIDcQNNpAfuiwIUsc4jVoTxbkq3ajJyvboQqRfjORm36NVivy228wsCcQhdfkw2iCHgySz9p_I1egQu_8s-RJB8bj8-N5kXy5urxdLNPrT-9Xi3fXqSozEdK2Y01JoShY1maCZZQzbAtgVdWoktVNEXfSdVAxipQLwWnHOKty1kBOVcdqdpG8PegOYxN3qeI0DowcnN7FkWUPWv77YvVGrvvvkkdpXk4Cr44Crr8b0Qe5016hMWCxH73Ma8FEdBQT-vIBuu3HKUQvaZYXnBW0qCJVHyjleu8ddqfP5JmcspcPs5e8lFP2sfXF38OcGv-EHYGPB2DrA6zxBIALWhn8r7KYytHhBKoNOImW_QJ7sdBx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014534247</pqid></control><display><type>article</type><title>Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Tsuchiya, Hiromi ; Kioka, Hidetaka ; Ozu, Kentaro ; Ohtani, Tomohito ; Yamaguchi, Osamu ; Yazaki, Yoshikazu ; Yamauchi-Takihara, Keiko ; Sakata, Yasushi</creator><creatorcontrib>Tsuchiya, Hiromi ; Kioka, Hidetaka ; Ozu, Kentaro ; Ohtani, Tomohito ; Yamaguchi, Osamu ; Yazaki, Yoshikazu ; Yamauchi-Takihara, Keiko ; Sakata, Yasushi</creatorcontrib><description>Pulmonary arterial hypertension (PAH) is known to develop as a consequence of multiple genetic and/or non-genetic factors. A 27-year-old woman with chronic hepatitis C virus (HCV) infection developed severe PAH after interferon (IFN) therapy. Although most of the reported clinical courses of IFN-induced PAH are poor despite the discontinuation of IFN, the present patient was successfully treated with a triple combination therapy. In this report, we discuss the crosstalk among chronic HCV infection, IFN therapy, autoimmune disorders, and portal hypertension in the pathogenesis and development of PAH.</description><identifier>ISSN: 0918-2918</identifier><identifier>ISSN: 1349-7235</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.56.7822</identifier><identifier>PMID: 28458313</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adult ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Autoimmune diseases ; Case Report ; Chronic infection ; Female ; Genetic factors ; HCV infection ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Humans ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - etiology ; Infections ; Interferon ; interferon therapy ; Interferons - adverse effects ; Interferons - therapeutic use ; Internal medicine ; Liver ; portopulmonary hypertension ; Pulmonary hypertension ; Risk Factors ; Treatment Outcome ; up-front combination therapy ; Viruses</subject><ispartof>Internal Medicine, 2017/05/01, Vol.56(9), pp.1061-1065</ispartof><rights>2017 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><rights>Copyright © 2017 by The Japanese Society of Internal Medicine 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-df3b62a4430d0930253ed4a377bc638b4782ffa732e259952f353713ba12cf383</citedby><cites>FETCH-LOGICAL-c609t-df3b62a4430d0930253ed4a377bc638b4782ffa732e259952f353713ba12cf383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478568/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478568/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28458313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsuchiya, Hiromi</creatorcontrib><creatorcontrib>Kioka, Hidetaka</creatorcontrib><creatorcontrib>Ozu, Kentaro</creatorcontrib><creatorcontrib>Ohtani, Tomohito</creatorcontrib><creatorcontrib>Yamaguchi, Osamu</creatorcontrib><creatorcontrib>Yazaki, Yoshikazu</creatorcontrib><creatorcontrib>Yamauchi-Takihara, Keiko</creatorcontrib><creatorcontrib>Sakata, Yasushi</creatorcontrib><title>Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Pulmonary arterial hypertension (PAH) is known to develop as a consequence of multiple genetic and/or non-genetic factors. A 27-year-old woman with chronic hepatitis C virus (HCV) infection developed severe PAH after interferon (IFN) therapy. Although most of the reported clinical courses of IFN-induced PAH are poor despite the discontinuation of IFN, the present patient was successfully treated with a triple combination therapy. In this report, we discuss the crosstalk among chronic HCV infection, IFN therapy, autoimmune disorders, and portal hypertension in the pathogenesis and development of PAH.</description><subject>Adult</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Autoimmune diseases</subject><subject>Case Report</subject><subject>Chronic infection</subject><subject>Female</subject><subject>Genetic factors</subject><subject>HCV infection</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Infections</subject><subject>Interferon</subject><subject>interferon therapy</subject><subject>Interferons - adverse effects</subject><subject>Interferons - therapeutic use</subject><subject>Internal medicine</subject><subject>Liver</subject><subject>portopulmonary hypertension</subject><subject>Pulmonary hypertension</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>up-front combination therapy</subject><subject>Viruses</subject><issn>0918-2918</issn><issn>1349-7235</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkcGO0zAQhiMEYrsLr4AsceGSkthxEnNAQtUurbTACi1crYkzaV1cJ2s7QB9k3xeHlgpWXMay_M3_e-ZPEpJnc5qX4rW2AZ0Fs8NWK21xzst5VVP6KJnlrBBpRRl_nMwykdcpjeUsOfd-m2WsrgR9mpzRuuA1y9ksuV9NUh263pLbDToY9uTyJyh0DQRsyc1odr0FtyfL_YAuoPU6otoSIDcQNNpAfuiwIUsc4jVoTxbkq3ajJyvboQqRfjORm36NVivy228wsCcQhdfkw2iCHgySz9p_I1egQu_8s-RJB8bj8-N5kXy5urxdLNPrT-9Xi3fXqSozEdK2Y01JoShY1maCZZQzbAtgVdWoktVNEXfSdVAxipQLwWnHOKty1kBOVcdqdpG8PegOYxN3qeI0DowcnN7FkWUPWv77YvVGrvvvkkdpXk4Cr44Crr8b0Qe5016hMWCxH73Ma8FEdBQT-vIBuu3HKUQvaZYXnBW0qCJVHyjleu8ddqfP5JmcspcPs5e8lFP2sfXF38OcGv-EHYGPB2DrA6zxBIALWhn8r7KYytHhBKoNOImW_QJ7sdBx</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Tsuchiya, Hiromi</creator><creator>Kioka, Hidetaka</creator><creator>Ozu, Kentaro</creator><creator>Ohtani, Tomohito</creator><creator>Yamaguchi, Osamu</creator><creator>Yazaki, Yoshikazu</creator><creator>Yamauchi-Takihara, Keiko</creator><creator>Sakata, Yasushi</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors</title><author>Tsuchiya, Hiromi ; Kioka, Hidetaka ; Ozu, Kentaro ; Ohtani, Tomohito ; Yamaguchi, Osamu ; Yazaki, Yoshikazu ; Yamauchi-Takihara, Keiko ; Sakata, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-df3b62a4430d0930253ed4a377bc638b4782ffa732e259952f353713ba12cf383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Autoimmune diseases</topic><topic>Case Report</topic><topic>Chronic infection</topic><topic>Female</topic><topic>Genetic factors</topic><topic>HCV infection</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Infections</topic><topic>Interferon</topic><topic>interferon therapy</topic><topic>Interferons - adverse effects</topic><topic>Interferons - therapeutic use</topic><topic>Internal medicine</topic><topic>Liver</topic><topic>portopulmonary hypertension</topic><topic>Pulmonary hypertension</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>up-front combination therapy</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuchiya, Hiromi</creatorcontrib><creatorcontrib>Kioka, Hidetaka</creatorcontrib><creatorcontrib>Ozu, Kentaro</creatorcontrib><creatorcontrib>Ohtani, Tomohito</creatorcontrib><creatorcontrib>Yamaguchi, Osamu</creatorcontrib><creatorcontrib>Yazaki, Yoshikazu</creatorcontrib><creatorcontrib>Yamauchi-Takihara, Keiko</creatorcontrib><creatorcontrib>Sakata, Yasushi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuchiya, Hiromi</au><au>Kioka, Hidetaka</au><au>Ozu, Kentaro</au><au>Ohtani, Tomohito</au><au>Yamaguchi, Osamu</au><au>Yazaki, Yoshikazu</au><au>Yamauchi-Takihara, Keiko</au><au>Sakata, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>56</volume><issue>9</issue><spage>1061</spage><epage>1065</epage><pages>1061-1065</pages><issn>0918-2918</issn><issn>1349-7235</issn><eissn>1349-7235</eissn><abstract>Pulmonary arterial hypertension (PAH) is known to develop as a consequence of multiple genetic and/or non-genetic factors. A 27-year-old woman with chronic hepatitis C virus (HCV) infection developed severe PAH after interferon (IFN) therapy. Although most of the reported clinical courses of IFN-induced PAH are poor despite the discontinuation of IFN, the present patient was successfully treated with a triple combination therapy. In this report, we discuss the crosstalk among chronic HCV infection, IFN therapy, autoimmune disorders, and portal hypertension in the pathogenesis and development of PAH.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>28458313</pmid><doi>10.2169/internalmedicine.56.7822</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2017/05/01, Vol.56(9), pp.1061-1065 |
| issn | 0918-2918 1349-7235 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5478568 |
| source | J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access |
| subjects | Adult Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Autoimmune diseases Case Report Chronic infection Female Genetic factors HCV infection Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Humans Hypertension Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - etiology Infections Interferon interferon therapy Interferons - adverse effects Interferons - therapeutic use Internal medicine Liver portopulmonary hypertension Pulmonary hypertension Risk Factors Treatment Outcome up-front combination therapy Viruses |
| title | Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon%20Therapy%20Exacerbated%20Pulmonary%20Hypertension%20in%20a%20Patient%20with%20Hepatitis%20C%20Virus%20Infection:%20Pathogenic%20Interplay%20among%20Multiple%20Risk%20Factors&rft.jtitle=Internal%20Medicine&rft.au=Tsuchiya,%20Hiromi&rft.date=2017-01-01&rft.volume=56&rft.issue=9&rft.spage=1061&rft.epage=1065&rft.pages=1061-1065&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.56.7822&rft_dat=%3Cproquest_pubme%3E2014534247%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014534247&rft_id=info:pmid/28458313&rfr_iscdi=true |